Apr 13, 2017
OTC Disclosure & News Service
Mesquite, NV – CBDS
CANNABIS SATIVA, INC. CLOSES ITS ACQUISITION OF THE WHITE RABBIT INTELLECTUAL PROPERTY AND ENTERS INTO LICENSE AGREEMENT FOR CALIFORNIA SALES
MESQUITE, NV / ACCESSWIRE / April 13, 2017 / Cannabis Sativa. Inc. (OTCQB:CBDS) announced today that the Company has entered into a license agreement for the manufacture, marketing and sale of the Company’s White Rabbit products in the State of California. The Company anticipates adding products to its California licensing agreement in the coming months. Moreover, the Company is seeking to engage additional licensees in states where medical cannabis is legal.
The Company announces that it closed its acquisition of the White Rabbit brand of cannabis sprays and cannabis mints (www.enjoywhiterabbit.com). The acquisition includes the exclusive and proprietary product formulations, product mixes, manufacturing methods and branding. The White Rabbit product line currently consists of fast acting low dose cannabis oral sprays and popular low dose cannabis mints. Both the spray and the mints are formulated as CBD only, THC only and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1 and 20:1 variations of each.
The Company’s President David Tobias stated, We are pleased with the White Rabbit product and are excited about the relationship being developed in the California market.
This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company’s success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.